MustGrow Biologics (MGRO) Corporate Presentation summary

Market opportunity and industry trends

• Global fertilizer and pesticide market projected at $380B by 2032, with biologics and regenerative products as the fastest-growing segment.

• Increasing regulation on synthetic chemicals and growing demand for organic solutions worldwide.

• 162 countries have banned 460 pesticide active ingredients, driving need for alternatives.

• Bayer aims to shape regenerative agriculture on over 400 million acres by mid-2030s.

• EU targets 25% of land under organic farming by 2030.

Product portfolio and commercialization

• TerraSANTE is a registered biofertility product in key US states, targeting high-value and organic crops.

• TerraMG is a pre-registered biocontrol product for soil-borne diseases, with ongoing registration in North America and EMEA.

• Commercial sales expansion includes US, Canada, and international markets, with partnerships for production and distribution.

• Bayer partnership in EMEA includes significant investment and milestone payments.

• NexusBioAg division leverages existing sales channels and third-party product licensing.

Financials and capital structure

• 1H 2025 revenues reached $6.6M, with NexusBioAg contributing C$15-20M in historic annual revenue.

• 58.9M shares outstanding, C$40M market cap, and 20% management and advisor ownership.

• Cash position at June 30, 2025: $1.82M; debt: $0.52M; previous capital spent: $30M.

• Low capex, asset-light model with scalable production through contract manufacturers.

• Every 50,000 acres of TerraSANTE sales could generate C$39M in product revenue.